Drugs / VS-041
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07219511 | Nov 2025 → Jun 2026 overdue | diastolic heart failure | Vasa Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07219511 ↗ |
| Route | Oral | “VS-041 high dose, VS-041 low dose or Placebo tablet BID” NCT07219511 ↗ |